Myomectomy Market Saw a Huge Surge in 2018 | An inside look about Myomectomy Industry and Why its Booming

Myomectomy a surgical procedure for the removal uterine fibroids. Uterine fibroids are common noncancerous growth in the uterus of women at their child bearing age, causing symptoms such as heavy bleeding during menstrual cycle, increased menstrual cramping, pain in pelvis or lower back, and swelling enlargement of the abdomen. Myomectomy differs from hysterectomy. During myomectomy, the surgeons remove only the fibroids in the uterus while in hysterectomy entire uterus is removed. This procedure preserves the chances of women getting pregnant. There are four types of myomectomy namely; abdominal, hysteroscopic, laparoscopic, and robotic. Results of myomectomy are found to be better and women report improvement in fibroid symptoms, such as heavy menstrual bleeding and pelvic pressure.

Rising prevalence of uterine fibroids, and increasing demand for diagnosis and treatment of uterine disorder. Additionally, increasing demand for medical devices for gynecology procedures also fuel the growth of the market. Furthermore, increasing healthcare expenditure and overall growth of healthcare industry also influence the market growth. Splendid research in the field of reproductive health and diseases also boost the market.

The growth of medical device industry and increasing demand for technological advanced medical devices also fuels the growth of the market across the globe. However, the growth of the market is restricted due to increasing competition among existing players and high cost of medical devices.

According to the U.S. Department of Health and Human Services office on Women Health, about 20% to 80% of women develop fibroids by the age of 50 and nearly 30% will get them at the age of 35. Uterine fibroids are most common in women in their 40s and early 50s. Not all women with fibroids have symptoms; nearly 45% to 50% of the women do not exhibit symptoms in their lifespan. Increase in the age also affect the prevalence rate of uterine fibroids.

The global myomectomy market is expected to grow at a CAGR of 6.9% during the forecast period.

Get Sample Copy of Report At: https://www.marketresearchfuture.com/sample_request/5149

Myomectomy Market Key Companies Analyzed In Report Are:

Halt Medical, Inc. (U.K), Boston Scientific Corporation (U.S.), CooperSurgical Inc. (U.S.), C. R. Bard, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), General Electric Company (U.S.), KARL STORZ SE & Co. KG (Germany), Richard Wolf Medical Instruments (U.S.), Siemens (U.S.), AbbVie Inc. (U.S.), Bayer (Germany), Eli Lilly and Company (U.S.), Johnson & Johnson Services Inc. (U.S.) and others.

Market Segmentation:

The global myomectomy market is segmented on the basis of type, product, and end user. On the basis of type, market is segmented into abdominal, hysteroscopic, laparoscopic, and robotic. On the basis of product, the market is segmented into laparoscopic power morcellators, harmonic scalpel, laparoscopic sealer, and others. On the basis of end user, the market is segmented into hospitals & clinics, surgical centers, medical device companies, and others.

Get Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/5149

Detailed Regional Analysis:

America holds the first position in the market for myomectomy owing to the rising prevalence of uterine disorders in the U.S., and increasing demand for new diagnostic and treatment services. In Americas, North America is the largest market owing to the presence of key players in healthcare IT industry. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.

Europe is the second largest market for myomectomy. In Europe, there is an increasing demand for medical devices and availability of funds for research and development activities in the reproductive health. The growth of surgical devices in Germany, France, and U.K also fuels the growth of the market.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing women suffering from uterine disorders, and rising investment in surgical device industry by key players in developing economies throughout Asia Pacific. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand technologically advanced medical devices such as gene chips for research activities, and availability of highly qualified medical professional such as surgeons and gynecologists.

The Middle East & Africa also show a steady rise in the market owing to low technology penetration and increasing awareness about diagnosis and treatment of uterine fibroids. In the Middle East & Africa, Middle East captures the largest market share for myomectomy owing to the availability of better healthcare infrastructure, availability of specialty services and wide scope for research.

Some of the Major TOC:

1. Report Prologue

2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Browse more on “Myomectomy Market Research Report- Forecast 2023” at: https://www.marketresearchfuture.com/reports/myomectomy-market-5149

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
Office No-528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune — 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.